Entero Therapeutics Quote - ENTO

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

0.63

Bid

0.581

Ask

0.698

Volume

64,938

0.5735 Day's Range 0.6615

0.185 52 Week Range 3.16

Previous Close

0.6184

Open

0.5998

Last Trade

0.5805

Last Trade Time

Average Volume (3m)

483,346

Financial Volume

US$ 39,579

VWAP

0.609482

Form 8-K - Current report

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0134	-2.08268573205	0.6434	0.67	0.5214	93098	0.57343265	CS
4	0.24	61.5384615385	0.39	0.926	0.39	333651	0.72331854	CS
12	0.271	75.4874651811	0.359	0.926	0.32	483346	0.61540454	CS
26	-1.28	-67.0157068063	1.91	2.29	0.185	516831	0.48831769	CS
52	-2.33	-78.7162162162	2.96	3.16	0.185	444160	0.50209824	CS
156	-2.33	-78.7162162162	2.96	3.16	0.185	444160	0.50209824	CS
260	-2.33	-78.7162162162	2.96	3.16	0.185	444160	0.50209824	CS

ENTO - Frequently Asked Questions (FAQ)

What is the current Entero Therapeutics share price?

The current share price of Entero Therapeutics is US$ 0.63

What is the 1 year trading range for Entero Therapeutics share price?

Entero Therapeutics has traded in the range of US$ 0.185 to US$ 3.16 during the past year

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MYSZMy Size Inc	US$ 4.2001 (211.12%)	121.03M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	78.06M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	34M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.94k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	121.95M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.91M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.75M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.94M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	9.27M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	6.25M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.33M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	310.19M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	306.25M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	293.22M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	281.23M